



Institutional Biosafety Committee Meeting

Meeting Minutes

Date: June 3, 2025

Call to order: 1:01 PM (PDT)

Location: MS Teams

Voting members

Member Name	Role	Attendance
[REDACTED]	IBC Chair	+
[REDACTED]	Corporate BSO	+
[REDACTED]	NM Site BSO	+
[REDACTED]	Committee Member	Absent
[REDACTED]	Committee Member	+
[REDACTED]	Committee Member	Absent
[REDACTED]	Committee Member	+
[REDACTED]	Committee Member	+
[REDACTED]	Committee Member	+
[REDACTED]	Committee Member	Absent
[REDACTED]	Committee Member	+
[REDACTED]	Committee Member	+

IBC Chair opened the meeting by welcoming everyone to our June IBC meeting and confirmed we have a quorum.

[REDACTED] announced changes to the committee membership: [REDACTED] and [REDACTED] have stepped down, while [REDACTED] and [REDACTED] have joined as new members.

Review of Previous Minutes

Minutes from April 15, 2025 approved: ☒ Yes ☐ No

Motion: ☒ Approve ☐ Approve with Modifications ☐ Table ☐ Disapprove

Vote Count: Yes: _4_ | No: ____ | Abstain: _4_



PROTOCOL REVIEWS

1:05 PM

2026-06-03-CS - Deep mutational scanning for antiviral countermeasure optimization

Action: New

Work Planner: [REDACTED]

Presenter: [REDACTED]

Containment: BSL2

NIH Guidelines: III-D-3

The discussion centered on a potential Dual Use Research of Concern (DURC) issue related to the protocol's focus on viral glycoprotein mutagenesis and antibody escape profiling. Following thorough consideration of the associated risks and proposed mitigations, the committee found them acceptable and approved the protocol as submitted. Any mutations suspected of raising DURC concerns will be referred to the appropriate DURC review process outside the scope of the IBC.

Motion: ☒ Approve ☐ Approve with Modifications ☐ Table ☐ Disapprove

Vote Count: Yes: 9 | No: | Abstain:

Conflict of Interest Noted: ☒ Yes (Name: , recused) ☐ No

1:25 PM

2026-06-02-BR - Innate Immunity Peptide Studies

Action: New

Work Planner: [REDACTED]

Presenter: [REDACTED]

Containment: BSL2

NIH Guidelines: N/A

The protocol was reviewed, and the following modifications/contingencies have been requested:

1. Although the peptide is described as non-toxic, please provide a reference supporting its toxicity profile and specify the quantity being used in the protocol.

Motion: ☐ Approve ☒ Approve with Modifications ☐ Table ☐ Disapprove

Vote Count: Yes: 9 | No: | Abstain:

Conflict of Interest Noted: ☐ Yes (Name: , recused) ☒ No

Meeting adjourned at 2:00 PM PDT

Next Meeting: August 5, 2025